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▪ There are growing concerns among European payers about the 
rising costs of new medicines especially for cancer and those 
for orphan diseases, exacerbated by the emotive nature of 
these disease areas – balanced against continued unmet need
▪ This is despite the limited health gain of most new medicines 
coupled with the low cost of goods of most including biological 
medicines. Alongside this, CEE countries are struggling to fund 
biological medicines for immunological diseases at Euro 1000 
– 1500/ patient/ month – although easier with biosimilars 
▪ This is leading to developments including new models for new 
medicines incorporating new pricing approaches for orphan 
diseases, calls for greater transparency in price negotiations 
with concerns with MEAs, development of European 
collaborations and position statements (EURODIS), and 
greater use of low cost generics and biosimilars
Prices and access to new medicines are key issues in 
Europe balanced against considerable unmet need 
Ref: Godman et al 2015, 2018; Kostic et al 2017; EURORDIS 2018; Luzzatto et al 2018; Baumgart 2019
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Prescrire believes very few new drugs and 
indications are advances - most minor advance 
or similar to existing drugs/ indications
Ref: Godman et al 2015, 2018; Prescrire 2016, 2018 
Prescrire ratings 2006 2008 2010 2012 2014 2015
Innovative drug/ real 
therapeutic advance 2 0 1 1 3 3
Offers an advantage 
(modest) 8 6 3 3 5 5
Possibly helpful 31 25 22 14 15 15
Nothing new 69 57 49 42 35 43
Not acceptable including 
safety concerns 17 23 19 15 19 15
Judgement reserved - 
usually due to 
insufficient data 8 9 3 7 10 6
Total 135 120 97 82 87 87
In 2017 out of 92 medicines only 1 real advance and 2 with 
modest benefits
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▪ Of the 12 drugs approved by the FDA for various cancers in 
2012:
❑ 9 were priced at more than US$10,000/patient/ month
❑ Only 3 prolonged survival, 2 by less than 2 months
▪ Of the 7 targeted therapies for renal cell carcinoma approved in 
the US between 2005 and 2012:
❑ all improved progression-free survival (PFS) by typically 3 
to 6 months
❑ However, minimal or no impact on overall survival at a cost 
of US$70,000 to US$140,000/ patient annually
▪ Recent studies have shown that the cost of goods of some new 
cancer medicines can be as low as 1% of the selling price. New 
medicines for hepatitis C also have low cost of goods resulting 
initially in gross profit expectations of over 99.9% in Europe 
Ref: Kantarjian  et al 2013; Phelan et al 2014; Godman et al 2015-2019; Hill et al 2017
This is seen also for new cancer medicines 
causing concern with ever increasing prices
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Ref: Godman et al 2019
The cost 
of goods 
of new 
cancer 
medicines 
can be 
very low 
as seen 
with 
imatinib 
with 
generics
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This mirrors low 
prices for other oral 
generics e.g. generic 
omeprazole in the 
Netherlands 
(similarly for generic 
simvastatin) with 
their preference 
pricing policy
Appreciable price 
reductions are also 
likely with 
biosimilars in time 
with e.g. Abbvie 
offering HUMIRA at a 
89% discount in the 
Netherlands to try 
and prevent 
biosimilar entry
Ref: van Woerkom, Pipenbrink; Moorkens 2017 and being submitted  
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Continuing high prices for new cancer medicines despite 
often limited health gain – driven by the emotive nature 
of the disease area - is resulting in these headlines 
Potential ways forward include establishing minimum threshold 
levels for granting premium prices for new cancer medicines
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Proposed minimum criteria have centred on 3 months 
additional survival – first proposed in the UK in 2000 
We also recently critiqued the ESMO criteria for valuing new cancer 
medicines and proposed a number of adaptations based on overall 
survival to take account of increasing budgetary issues and concerns 
with surrogate markers such as objective response rates and PFS -
especially in solid tumours 
Ref: Ferguson et al 2000; Wild et al 2016
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Concerns with ever increasing prices for new medicines 
for orphan diseases is resulting in publications such as 
Luzzatto et al in the Lancet in 2018. However an 
appreciable number have annual costs less than 
Euro1000/ patient/ month
Ref: EURORDIS 2018; Luzzatto et al 2018
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Pressure from the media in 
the Netherlands resulted in 
pressure on the MoH to 
ignore the advice of the 
reimbursement agency about 
funding enzyme replacement 
therapy for Fabrys’ disease 
(up to €3.3 million 
incremental cost / QALY) and 
up to €15million for 
alglucosidase alfa to treat 
Pompe’s disease
Such situations cannot 
continue for the sustainability 
of European healthcare 
systems – leading to the TVF 
for new biological medicines 
for orphan diseases
Ref: Simoens et al 2013; Godman et al 2015, 2016 
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▪ The same pressures are continuing with lumacaftor/ivacaftor for CF 
patients who are homozygous for the F508del mutation (45%). After 
24 weeks, there was a statistically significant improvement in ppFEV1 
(2.6–3 - 4%) – however seen as uncertain clinical significance - and 
pulmonary exacerbations were less (although not significant). In 
addition, 73% with Orkambi failed to achieve an absolute 
improvement of at least 5% in ppFEV1
▪ In the 96-week extension study (PROGRESS trial), the mean absolute 
change in ppFEV1 remained above baseline in patients continuing 
with Orkambi - however, the difference from baseline was no longer 
statistically significant (and certainly limited clinical significance)
▪ This may though mask appreciable benefits in some patients
▪ In view of concerns with the overall extent of health gain coupled 
with requested prices – Orkambi was initially rejected by NICE. 
Similarly rejected in Canada by CDR at an estimated ICER of 
Ca$4.8million/ QALY when compared to current standards of care
▪ However in England following pressure and additional discounts - the 
decision has recently been reversed – following the lead in Scotland 
Patient and media pressures have resulted in Orkambi 
(lumacaftor/ivacaftor) being funded despite concerns 
Ref: NICE TA398 2016; CDR 2016; Australian Prescriber 2019; Hollis 2019 
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Orkambi was 
recently funded 
in England  
following 
appreciable 
pressure from 
the media and 
patients. 
Some patients 
though have 
appreciably 
benefited from 
Orkambi
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▪ ‘Class action suit raises questions about how Canada funds 
drugs to treat rare diseases’ – headline in Vancouver Star 26 July 
2018 – with Chris MacLeod launching a class action suit seeking $60 
million in damages on behalf of patients refused coverage of Orkambi
▪ While the costly medication is covered by some health plans (Private) 
in Canada - not approved for funding by provincial/ federal 
governments due to lack of cost effectiveness (ICER of Ca$4.8mn)
▪ However, MacLeod said Orkambi can be life-changing for some 
patients and that they have the right to this medicine under Section 
7 of the Charter, which guarantees that “everyone has the right to 
life, liberty and security of the person”
▪ Likely to see similar media/ activities in other countries to try and 
enhance funding for Orkambi despite the costs and benefits involved
• Nobody though is challenging the gross profit being made by the 
companies involved with the NPV of these medicines estimated at 
$33billion in 2013 – with royalty expenses and production costs 
averaging just 12.6% of revenues. This needs to change for the 
future sustainability of healthcare systems 
There is an ongoing class action in Canada for Orkambi as 
a result of differences in funding between organisations
Ref: CDR 2016; Vancouver Star 2018; Hollis 2019  
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There has been variable 
use of biological 
medicines to treat 
patients with rheumatoid 
arthritis across Europe in 
recent years
Putrik at al in 2014 
showed considerable 
variation depending on 
issues of socioeconomic 
status, co-payments and 
disease severity
High scores were 
associated with good 
access 
Ref: Putrik et al 2014
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There is also 
considerable 
variation in the 
use of biologicals 
in patients with 
inflammatory 
bowel disease 
across Europe 
driven again by 
issues of access 
and affordability
Kostic et al in 
Serbia also found 
limited use of 
biologicals for 
IBD due to high 
patient co-
payments 
Ref: Kostic et al 2017; Baumgart et al 2019
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▪ Improved pro-active planning by health authorities starting 
with Horizon Scanning as well as greater co-operation over 
HTA assessments (e.g. Nordic group) will help. This includes 
early dialogue with pharmaceutical companies
▪ Companies actively reducing the disconnect between the 
potential health gain of a new medicine and their price –
especially if considerable uncertainty exists (reducing with 
initiatives such as TRUST4RD) – enhanced with the recent 
experience with Olaratumab across Europe
▪ Greater transparency regarding requested prices to aid 
discussions – especially with ageing populations across 
Europe. MCDAs have also been proposed to assist with pricing 
negotiations as an alternative to cost/ QALYs/ ICERs by MOCA
▪ Researching potential new funding approaches – and greater 
co-operation among payers building on current networks
Potential ways forward include better planning and co-
ordination by payer groups, MCDAs and realistic prices
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2-3 years before likely 
EMA authorisation
1 year from 
EMA 
authorisation 
EMA 
authorization
Reimbursement
(National and 
Regional)
Horizon scanning (in 
association with others)
Evaluation  risk 
sharing arrangements
Guidelines on use with 
key physician groups 
especially where concerns 
– possibly addressing PR
Additional 
regional 
restrictions
Evaluate adherence to agreed 
guidance/ guidelines/ restrictions. 
Initiate additional demand-measures 
if needed
Patient follow-up on 
effectiveness and safety in 
practice using registries or 
EHRs
Assess budget impact based 
on likely patient numbers 
and perceived ’value’ with 
key groups. Start 
discussions on patient 
registries (if pertinent)
Time lines Pre- and Peri- Launch
Peri and post-launch activities
Communication programmes 
with key stakeholder groups 
Ref: Malmstrom, Godman et al 2013; Godman, Malmstrom et al 2014
Improved managed entry of new medicines is growing in Europe
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Stockholm County Council and now across Sweden has a well developed system for 
Horizon Scanning, feeding into funding and procurement decisions and follow-up 
post launch. In Stockholm, horizon scanning activities feed into annual forecasts for 
medicines across disease areas to help with planning
Ref: Eriksson et al 2017; Godman et al 2016, 2018
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WHO Resolution “Improving the 
transparency of markets for drugs, 
vaccines and other health-related 
technologies” adopted during the 72nd
session of the World Health Assembly in 
May 2019. 
- proposed by IT, co-sponsored by 
other countries including a number of 
countries signatory to the Valletta 
Declaration;
- implementation of the 
recommendations.
Ref: Ferrario et al 2017; Godman et al 2018; Hon. Chris Fearne WODC Barcelona 2019
Addressing some of the concerns with managed 
entry agreements and different confidential 
discounts being offered across European countries 
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The Transparent Value Framework (TVF) was developed by key 
stakeholders as part of the MoCA-OMP project following the 
situation in the Netherlands to provide guidance for the pricing 
new medicines for orphan diseases and is still being evaluated. 
Other MCDAs have also been proposed as potential ways forward
Ref: MOCA – ongoing; WHO Europe 2015; Godman et al 2015, 2018
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Such approaches are 
also included in 
EURORDIS’ Vision 
that they would like 
to see 3 to 5 times 
more new rare 
disease therapies 
approved per year, 3 
to 5 times cheaper 
than today, by 2025 
to benefit all 
European citizens 
with rare diseases 
especially those in 
CEE countries
Ref: EURORDIS 2018
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▪ Ongoing developments with the various pan-EU country co-
operations - combined with greater proactivity pre-launch 
through to post launch - will enhance objectivity in pricing and 
funding negotiations for new medicines and their place in 
therapy. In time, this should help accelerate funding for new 
medicines that truly benefit patients and limit funding for new 
premium priced medicines with limited health gain
▪ We are also likely to see further pricing models to enhance the 
opportunity for all European citizens to benefit from new 
valued medicines. At the same time, encourage greater use of 
generics and biosimilars without compromising care to ease 
budgetary pressures
▪ In addition, potential re-evaluation of the role/ value of 
patented medicines once the comparator medicine used in 
negotiations becomes available as a generic/ biosimilar
New systems and co-operation are needed to ensure fair 
pricing for medicines to maintain UHC for all in Europe
AIM Fair Prices Pharmaceuticals 201926
Thank You
Any Questions!
Brian.Godman@ ki.se; 
Brian.Godman@liverpool.ac.uk; 
Brian.godman@strath.ac.uk; 
briangodman@outlook.com
